Navigation Links
Epizyme, Inc. Reports Second Quarter 2013 Financial Results
Date:7/31/2013

CAMBRIDGE, Mass., July 31, 2013 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today provided a corporate update and reported financial results for the second quarter ended June 30, 2013.

"The second quarter was transformative for Epizyme. We completed a successful IPO, ending the period with $149 million in cash and cash equivalents," commented Robert Gould, Ph.D., CEO of Epizyme. "We now have two programs in clinical development. The dose escalation study is ongoing for EPZ-5676, our therapeutic candidate for the treatment of acute leukemia patients with mixed lineage leukemia (MLL-r), and we plan to initiate the expansion cohort stage of this study later this year. In June, we initiated clinical development of our second program, EPZ-6438, our therapeutic candidate for the treatment of non-Hodgkin lymphoma patients with oncogenic point mutations in EZH2. As a result of the initiation of the clinical development of EPZ-6438, we earned a $6 million milestone from our partner Eisai, which was received in July. Our collaborations with Celgene, Eisai, and GSK are important elements of our business strategy, including our retained United States rights for EPZ-5676 and EPZ-6438, and as sources of potential future milestones and royalties. Today, we are in a strong position to invest in and expand Epizyme's product platform and pipeline of therapeutic programs. We look forward to additional progress across the Company this year."

Recent Business Highlights

  • Completion of Initial Public Offering Epizyme announced on June 5, 2013, that it had completed its initial public offering of common stock, raising gross proceed
    '/>"/>

  • SOURCE Epizyme, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. China Medical Flat Panel Detector Market & Pressure Injector 2013 Research Reports Now Available at ReportsnReports.com
    2. Global Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline: MarketResearchReports.Biz
    3. Arena Pharma, Geron, Incyte, and Spectrum Pharma Under AAAResearchReports.com Microscope
    4. China Radiotherapy Simulator Market & Digital Radiography 2013 Research Reports Now Available at ReportsnReports.com
    5. Neurocrine Biosciences Reports Second Quarter 2013 Results
    6. United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
    7. Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2013
    8. Global Activated Carbon Market 2012-2016: Latest Market Share, Growth, Analysis, Size, Trends & Forecast Research Report 2012-2016 Available at Marketresearchreports.biz
    9. Cepheid Reports 2013 Second Quarter Results
    10. Quest Diagnostics Reports Second Quarter 2013 Financial Results
    11. Global GIS Market in the Retail Industry to 2016: Industry Analysis, Growth, Strategy, Size, Shares, Trend and Forecast Research Report Available at MarketResearchReports
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... , Pennsylvanie, 18 septembre 2014 ... en 1974, a été depuis 40 ... les évaluations cliniques traditionnelles par des évaluations ... et sur les impacts économiques des traitements. ... A cours d,une récente ...
    (Date:9/18/2014)...   Sigma-Aldrich Corporation (Nasdaq: ... a new gene editing partnership with the University ... the partnership, Sigma-Aldrich will provide the Vector Core ... dedicated gene editing bioinformaticians. The partnership ... the U-M Medical School. One initiative already underway, ...
    (Date:9/18/2014)... 2014 OMICS Group International invites ... participate in the ‘Open Access Week’ by actively ... OMICS Group Pharma Journals from 20-26th October, ... fastest emerging Sciences, accelerating with a tremendous speed ... the globe. The industry is gearing with innovation ...
    (Date:9/18/2014)... SeqLL Inc., the owner of ... today the closing of a $1M Series-A funding ... Diagnostic Technologies, will increase the power of tSMS™ ... in March 2013 by Daniel Jones, a former ... BioSciences, SeqLL has continued to offer Helicos’ sequencing ...
    Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2
    ... ... sectors suffer, savvy investors like Prudential target healthcare , ... Minneapolis (Vocus) – Even as other commercial real ... healthcare real estate. Recent deals have included $250 million in new debt and $30 ...
    ... , BETHESDA, Md., July 30 Micromet, Inc. ... proprietary antibodies for the treatment of cancer, inflammation and autoimmune ... 14,000,000 shares of its common stock at a public offering ... are being offered by Micromet. The gross proceeds to ...
    ... , , , ... CRTX ), a specialty pharmaceutical company focused ... the respiratory and related markets, today announced that it ... a leading European pharmaceutical company headquartered in Parma, Italy. ...
    Cached Biology Technology:Millions Flowing into Medical Real Estate 2Millions Flowing into Medical Real Estate 3Micromet Announces Pricing of Public Offering of Common Stock 2Micromet Announces Pricing of Public Offering of Common Stock 3Micromet Announces Pricing of Public Offering of Common Stock 4Cornerstone Therapeutics Announces Closing of Chiesi Transaction 2Cornerstone Therapeutics Announces Closing of Chiesi Transaction 3Cornerstone Therapeutics Announces Closing of Chiesi Transaction 4Cornerstone Therapeutics Announces Closing of Chiesi Transaction 5Cornerstone Therapeutics Announces Closing of Chiesi Transaction 6
    (Date:9/18/2014)... that when people are too stressed they are often ... Brain Mind Institute (BMI) at EPFL have just highlighted ... chronic stress and the loss of social skills and ... a synaptic regulatory molecule in the brain. This was ... . , Carmen Sandi,s team went to look ...
    (Date:9/18/2014)... world, are the ideal animal in which to study ... the ocean into tens of thousands of freshwater streams ... skeleton to adapt to the new environment. , Breeding ... have turned up one of the genes that controls ... that gene,s regulation in a freshwater population is associated ...
    (Date:9/18/2014)... invisible is probably the ultimate form of camouflage: you ... And this strategy is not as uncommon as you ... Baltimore County, USA, explains that the larval life stages ... one part of the anatomy that most creatures cannot ... eyes have to shield each individual eye unit with ...
    Breaking Biology News(10 mins):How stress tears us apart 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Transparent larvae hide opaque eyes behind reflections 2
    ... , This release is available in Spanish . ... Agriculture (USDA) scientists working as part of an international team have ... in the journal Nature reported today. The achievement ... speed up development of wheat varieties with enhanced nutritional value. ...
    ... part of their ongoing research on the role of ... Diabetes Center scientists, in collaboration with scientists at the ... associated with type 1 diabetes and other autoimmune diseases ... upcoming issue of Diabetes . Recent studies ...
    ... aestivum ) is one of the "big three" globally important ... Fully 35% of the world,s 7 billion people depend on ... scientists, including a group from Cold Spring Harbor Laboratory (CSHL), ... The study reveals the evolution of bread wheat ...
    Cached Biology News:USDA scientists and cooperators sequence the wheat genome in breakthrough for global food security 2USDA scientists and cooperators sequence the wheat genome in breakthrough for global food security 3Joslin researchers increase understanding of genetic risk factor for type 1 diabetes 2Bread wheat's large and complex genome is revealed 2Bread wheat's large and complex genome is revealed 3
    ... Last innovation from Magnetofection technology, SilenceMag ... system available. Simple, rapid and easy ... and non toxic. Specifically designed for ... silencing at very low doses of ...
    ... Purity is >95%NEN Radiolabeled Ligands\n\nReceptor-related research has ... of new radiolabeled ligands selected to keep ... wide range of products and services for ... 400 state-of-the-art radioligands. If you do not ...
    ... The Fluorescence Test Plate consists of an ... with Inert Organic Fluorescent Compounds embedded in ... used on BioTeks FLx800 and Synergy Multi-Detection ... for GLP compliance while reducing the need ...
    ... Feature Extraction Software reads and ... to prepare microarray data for ... * one 2-year license ... NFP/Academic accounts , * ...
    Biology Products: